Given that MAP3K1 is a serine/threonine kinase involved in multiple signaling pathways and that its loss-of-function mutations are known to drive tumorigenesis24, our findings suggest that kinase fusions may represent an alternative mechanism for kinase pathway activation in breast cancer, independent of mutational events. Here, MARK2 is linked to breast carcinoma.